MA27141A1 - DERIVES DE 3-AZABICYCLO[3.1.0]HEXANE SERVANT D'ANTAGONISTES DES RECEPTEURS D'OPIOiDES - Google Patents

DERIVES DE 3-AZABICYCLO[3.1.0]HEXANE SERVANT D'ANTAGONISTES DES RECEPTEURS D'OPIOiDES

Info

Publication number
MA27141A1
MA27141A1 MA27630A MA27630A MA27141A1 MA 27141 A1 MA27141 A1 MA 27141A1 MA 27630 A MA27630 A MA 27630A MA 27630 A MA27630 A MA 27630A MA 27141 A1 MA27141 A1 MA 27141A1
Authority
MA
Morocco
Prior art keywords
receptor antagonists
azabicyclo
opioid receptor
formula
hexane derivatives
Prior art date
Application number
MA27630A
Other languages
English (en)
Inventor
Stanton Furst Mchardy
Steven Donald Heck
Spiros Liras
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA27141A1 publication Critical patent/MA27141A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/04—Compounds containing oxirane rings containing only hydrogen and carbon atoms in addition to the ring oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

DEPOSANT Société dite: PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 22 Octobre 2001 60/338,511 Voir en annexe le titre de l'invention et le texte de l'abrégé Dérivés de 3-azabicyclo[3.1.0]hexane servant d'antagonistes des récepteurs d'opioïdes La présente invention propose un composé de formule (I), dans laquelle X, Q, n, R1, R2, R3, R4 R5, R6, R7, R8, R9 et R10 répondent aux définitions. Les composés de formule (I) sont actifs comme antagonistes des récepteurs d'opioïdes. La présente invention propose en outre des compositions pharmaceutiques et des méthodes thérapeutiques comprenant des composés de formule (I).
MA27630A 2001-10-22 2004-04-15 DERIVES DE 3-AZABICYCLO[3.1.0]HEXANE SERVANT D'ANTAGONISTES DES RECEPTEURS D'OPIOiDES MA27141A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33851101P 2001-10-22 2001-10-22

Publications (1)

Publication Number Publication Date
MA27141A1 true MA27141A1 (fr) 2005-01-03

Family

ID=23325099

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27630A MA27141A1 (fr) 2001-10-22 2004-04-15 DERIVES DE 3-AZABICYCLO[3.1.0]HEXANE SERVANT D'ANTAGONISTES DES RECEPTEURS D'OPIOiDES

Country Status (42)

Country Link
US (3) US7049335B2 (fr)
EP (1) EP1440059B1 (fr)
JP (2) JP4155522B2 (fr)
KR (1) KR100621292B1 (fr)
CN (1) CN100368398C (fr)
AP (1) AP1816A (fr)
AR (1) AR036905A1 (fr)
AT (1) ATE392415T1 (fr)
AU (1) AU2002329557B2 (fr)
BR (1) BR0213464A (fr)
CA (1) CA2463264C (fr)
CR (1) CR7317A (fr)
DE (1) DE60226161T2 (fr)
DK (1) DK1440059T3 (fr)
EA (1) EA006708B1 (fr)
EC (1) ECSP045077A (fr)
ES (1) ES2302839T3 (fr)
GE (1) GEP20084300B (fr)
GT (1) GT200200216A (fr)
HK (1) HK1072052A1 (fr)
HN (1) HN2002000299A (fr)
HR (1) HRP20040288A2 (fr)
HU (1) HUP0401884A2 (fr)
IL (2) IL161157A0 (fr)
IS (1) IS7187A (fr)
MA (1) MA27141A1 (fr)
MX (1) MXPA04003730A (fr)
MY (1) MY136580A (fr)
NO (1) NO329092B1 (fr)
NZ (1) NZ531807A (fr)
OA (1) OA12711A (fr)
PA (1) PA8556701A1 (fr)
PE (1) PE20030610A1 (fr)
PL (1) PL368919A1 (fr)
PT (1) PT1440059E (fr)
RS (1) RS25104A (fr)
SI (1) SI1440059T1 (fr)
SV (1) SV2004001363A (fr)
TN (1) TNSN04071A1 (fr)
UA (1) UA75714C2 (fr)
WO (1) WO2003035622A1 (fr)
ZA (1) ZA200402172B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60229224D1 (de) 2001-04-18 2008-11-20 Euro Celtique Sa Nociceptin-analoga
DE60226161T2 (de) * 2001-10-22 2009-07-02 Pfizer Products Inc., Groton 3-azabicyclo[3.1.0]hexan derivative als antagonisten der opioid rezeptoren
BRPI0409307A (pt) * 2003-04-14 2006-04-25 Pfizer Prod Inc derivados de 3-azabiciclo[3.2.1]octano
US20050043327A1 (en) * 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7153976B2 (en) * 2003-10-06 2006-12-26 Pfizer Inc. Purification process for an azabicyclo[3.1.0]hexane compound
AU2004281794B2 (en) * 2003-10-14 2010-04-22 Pfizer Products Inc. Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
BRPI0415459A (pt) * 2003-10-16 2006-12-19 Pfizer Prod Inc preparação de derivados de 3-azabiciclo[3.1.0]hexano
SI1745040T1 (sl) 2004-02-23 2010-04-30 Venue Glaxo Group Ltd Derivati azabiciklo(3.1.0)heksana, uporabni kot modulatorji dopaminskih receptorjev d3
WO2005085228A1 (fr) * 2004-03-05 2005-09-15 Banyu Pharmaceutical Co., Ltd. Dérivé cycloalkanopyridine
CA2590182A1 (fr) * 2004-12-14 2006-06-22 Shionogi & Co., Ltd. Derive de l'indolomorphinane avec carboxy en position 6'
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
GB0517191D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
US7592461B2 (en) * 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
WO2008075162A2 (fr) * 2006-12-15 2008-06-26 Pfizer Limited Composés pour le traitement d'un dysfonctionnement sexuel
TWI409067B (zh) * 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
TWI423801B (zh) 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
US7691878B2 (en) * 2007-08-27 2010-04-06 Theravance, Inc. Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
ES2390195T3 (es) * 2007-08-27 2012-11-07 Theravance, Inc. Compuestos de amidoalquil-8-azabiciclo(3,2,1)octano, como antagonistas del receptor opioide mu
US7947710B2 (en) * 2007-08-27 2011-05-24 Theravance, Inc. Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
WO2012042539A2 (fr) 2010-09-28 2012-04-05 Panacea Biotec Ltd Nouveaux composés bicycliques
US9663463B2 (en) * 2013-11-20 2017-05-30 Sanwa Kagaku Kenkyusho Co., Ltd. 3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purpose
RU2017144548A (ru) * 2015-05-20 2019-06-20 Санва Кагаку Кенкюсо Ко., Лтд. Кристаллическая соль нового производного 3-азабицикло[3.1.0]гексана и ее применение в медицине
CA3054122A1 (fr) 2017-03-02 2018-09-07 Sanwa Kagaku Kenkyusho Co., Ltd. Agent therapeutique pour troubles lies a la consommation d'alcool

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2099214A (en) * 1937-11-16 Process fob forming the sulphuric
US2099216A (en) * 1934-05-04 1937-11-16 Frederick H Nass Metal testing machine
US3004340A (en) * 1959-09-24 1961-10-17 Bernice L Collins Kitchen utensil
US3078282A (en) * 1960-01-02 1963-02-19 Bayer Ag Anthraquinone dyestuffs
IL86061A (en) 1987-04-16 1992-07-15 Lilly Co Eli Derivatives of trans-3,4-isomer of 4-methyl-4-phenyl-piperidines,process for their preparation and pharmaceutical compositions containing them
JPH04155522A (ja) * 1990-10-19 1992-05-28 Nec Corp ファースト・イン・ランダム・アウト回路
US5159081A (en) 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
NZ242117A (en) 1991-03-29 1994-11-25 Lilly Co Eli 4-phenylpiperidine derivatives and medicaments containing them
GB9725114D0 (en) * 1997-11-28 1998-01-28 Pfizer Ltd Treatment of pruritus
GB9810671D0 (en) 1998-05-18 1998-07-15 Pfizer Ltd Anti-pruritic agents
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB9912410D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912415D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912413D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US20020064825A1 (en) 2000-05-19 2002-05-30 Lewis Marilyn Evelyn Novel polypeptide
US20030207876A1 (en) * 2000-06-23 2003-11-06 Banks Bernard Joseph 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy
GB0015562D0 (en) * 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
US20020025948A1 (en) * 2000-06-23 2002-02-28 Banks Bernard Joseph 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
DE10042885A1 (de) * 2000-08-31 2002-03-14 Heidelberger Druckmasch Ag Bogentransportzylinder
DE60226161T2 (de) 2001-10-22 2009-07-02 Pfizer Products Inc., Groton 3-azabicyclo[3.1.0]hexan derivative als antagonisten der opioid rezeptoren
EP1513813B1 (fr) 2002-05-30 2005-11-02 Eli Lilly And Company Antagonistes de recepteur d'opioides
US20040204453A1 (en) 2003-04-14 2004-10-14 Pfizer Inc 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors
US7056930B2 (en) 2003-04-14 2006-06-06 Pfizer Inc. 2-Azabicyclo[3.3.1]nonane derivatives
US20050043327A1 (en) 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7153976B2 (en) 2003-10-06 2006-12-26 Pfizer Inc. Purification process for an azabicyclo[3.1.0]hexane compound

Also Published As

Publication number Publication date
AP1816A (en) 2008-01-04
RS25104A (en) 2007-02-05
IS7187A (is) 2004-03-18
EA006708B1 (ru) 2006-02-24
MY136580A (en) 2008-10-31
SV2004001363A (es) 2004-02-24
PT1440059E (pt) 2008-05-16
US20070054950A1 (en) 2007-03-08
HRP20040288A2 (en) 2004-12-31
HK1072052A1 (en) 2005-08-12
EP1440059B1 (fr) 2008-04-16
GEP20084300B (en) 2008-02-11
PA8556701A1 (es) 2003-07-28
CA2463264A1 (fr) 2003-05-01
CR7317A (es) 2006-08-09
CN100368398C (zh) 2008-02-13
PE20030610A1 (es) 2003-07-12
MXPA04003730A (es) 2004-07-23
GT200200216A (es) 2003-05-23
TNSN04071A1 (fr) 2006-06-01
ATE392415T1 (de) 2008-05-15
CA2463264C (fr) 2009-05-26
US7049335B2 (en) 2006-05-23
US20050171178A1 (en) 2005-08-04
BR0213464A (pt) 2004-11-09
WO2003035622A1 (fr) 2003-05-01
OA12711A (en) 2006-06-27
EA200400467A1 (ru) 2004-08-26
NZ531807A (en) 2006-03-31
PL368919A1 (en) 2005-04-04
US20030087898A1 (en) 2003-05-08
DK1440059T3 (da) 2008-07-14
IL161157A0 (en) 2004-08-31
IL161157A (en) 2009-09-01
JP2005511545A (ja) 2005-04-28
SI1440059T1 (sl) 2008-08-31
HN2002000299A (es) 2002-11-21
JP2008069169A (ja) 2008-03-27
NO20041626L (no) 2004-05-26
CN1610664A (zh) 2005-04-27
ES2302839T3 (es) 2008-08-01
AP2004003007A0 (en) 2004-06-30
AU2002329557B2 (en) 2008-07-31
DE60226161D1 (de) 2008-05-29
DE60226161T2 (de) 2009-07-02
ECSP045077A (es) 2004-05-28
KR20040048984A (ko) 2004-06-10
EP1440059A1 (fr) 2004-07-28
ZA200402172B (en) 2006-09-27
UA75714C2 (en) 2006-05-15
KR100621292B1 (ko) 2006-09-13
HUP0401884A2 (hu) 2005-01-28
JP4155522B2 (ja) 2008-09-24
NO329092B1 (no) 2010-08-23
AR036905A1 (es) 2004-10-13

Similar Documents

Publication Publication Date Title
MA27141A1 (fr) DERIVES DE 3-AZABICYCLO[3.1.0]HEXANE SERVANT D'ANTAGONISTES DES RECEPTEURS D'OPIOiDES
MA27452A1 (fr) Derives d'indole servant d'agonistes beta-2
MA26954A1 (fr) ALPHA-ARYLETHANOLAMINES ET LEUR UTILISATION COMME AGONISTES DES RECEPTEURS BeTA3-ADRENERGIQUES
MA27190A1 (fr) Derives de tropane servant de modulateurs de ccr5
MA27142A1 (fr) Derives de piperazine a activite antagoniste des recepteurs ccr1
MXPA02005596A (es) Derivados de carbamato con actividad antagonista para el rerceptor muscarinico.
MA27180A1 (fr) N-aryl-2-oxazolidinone-5-carboxamides et leurs derives, et leur utilisation comme agents antibacteriens
MA27840A1 (fr) Derives de (2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propylphenyle servant d'agonistes beta2
KR20050085991A (en) Compounds exhibiting thrombopoietin receptor agonism
PH12014500937A1 (en) 5-ht 1a receptor substype agonist
DE60208568D1 (de) Prostaglandinanaloga als ep4-rezeptoragonisten
MA27451A1 (fr) Derives de thiazole pour le traitement de troubles neurodegeneratifs
MA27439A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MA27573A1 (fr) Sinomenine et derives de sinomenine, synthese et utilisation.
MA27174A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4.
MA29839B1 (fr) Derives de carboxamides servant d'antagonistes des recepteurs muscariniques
MA26953A1 (fr) Derives de pipérazine pontés.
AP2002002664A0 (en) Cyclohexylamine derivative as subtype selective NMDA receptor antagonists.
MA27135A1 (fr) Agents antidiabetiques oraux
EP1798227A4 (fr) Agoniste du récepteur 5-ht3 de la sérotonine
MXPA04005076A (es) Derivados de 4-piperidinil alquilamina como antagonistas del receptor muscarinico.
MA27010A1 (fr) Derives d'ethers phenyliques d'heterocyclyle servant d'inhibiteurs selectifs de reabsorption de serotonine
EP1339710A4 (fr) Derives du 3-oxadiazol-5-yl-1-aminoalkyl-1h-indole
MXPA04006115A (es) Derivados de imidazoquinolina.
UA83870C2 (ru) Замещенные бицикло[3.1.1]гептаном производные бензимидазолона и хиназолинона как агонисты человеческих рецепторов orl1